Early Use of Ivabradine in Heart Failure

• Status: Unknown status
• Trial end date: 2019-12-23
• Target enrollment: 0
• Participant gender: All

Summary

The aim of the work is to Evaluate the efficacy, quality of life and safety of early addition of ivabradine to B-blocker in reduced EF heart failure patients after acute decompensation compared to the standard treatment.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ain Shams University
• Collaborator: Sadat City University
• Treatments: Bisoprolol

Criteria

Inclusion Criteria:

1. Patient with acute heart failure either newly diagnosed or decompensated heart failure after stabilization

2. Patients > 18 years old

3. Left ventricular ejection fraction less than 40 % of presumed irreversible etiology

4. Clinically stable 24-48 hours after admission

5. Sinus rhythm with heart rate above 70 bpm

6. No previous treatment with ivabradine

Exclusion Criteria:

1. Patients less than 18 years.

2. Arterial fibrillation before inclusion.

3. Ventricular dysfunction due to acute event (Myocarditis, AMI). 4- cardiogenic shock

5. Patients are taking drug interact with ivabradine. 6- carrier or candidate for pacemaker, heart transportation, cardiac surgery or other cardiovascular procedure